Episode 4: The Qualification Gap

A CDMO opportunity is not won by capacity announcements, MOUs, or press coverage of a competitor’s regulatory trouble. It is won through multi-year client qualification cycles, sustained GMP/FDA inspection performance, and demonstrated commercial-scale output across the specific modality a client needs. The WuXi AppTec designation created a genuine tailwind, but the timeline for that tailwind to convert into Indian order books is longer, and the qualification bar is higher, than most coverage of this opportunity acknowledges.Listen in. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit mypharmareviews.substack.com